title: ERKs activation and calcium signaling are both required for VEGF induction by vanadium in mouse epidermal Cl41 cells.
abstract: The previous studies have demonstrated that vanadium exposure can cause a variety of biological effects. However, the mechanisms involved in the biological effects caused by vanadium are not well understood. Our previous studies have shown that exposure of mouse epidermal Cl 41 cells to vanadate stimulated the phosphorylation of both ERKs and p38K, and calcium signaling leading NFAT activation. In view of the evidence that ERKs and p38 kinase contribute to VEGF induction, we investigated in the present study the potential roles of ERKs, p38K, and calcium signaling in VEGF induction caused by vanadium exposure. Exposure of Cl 41 cells to vanadium led to VEGF induction in both time- and dose-dependent manners. Pre-treatment of Cl 41 cells with PD98059, an inhibitor of MEK1/2-ERKs pathway, but not SB202190, an inhibitor for p38K pathway, resulted in a dramatic inhibition of VEGF induction by vanadium. More interesting, pre-treatment of Cl 41 cells with intracellular calcium chelator, but not calcium channel blocker, resulted in a dramatic decrease in VEGF induction by vanadium. However, both PI-3K inhibitors and overexpression of Deltap85, a dominant negative PI-3K mutant, resulted in only a marginal decrease in VEGF induction by vanadium. Moreover, mTOR, as a downstream molecule of PI-3K, did not attribute to VEGF induction by vanadium because rapamycin pre-treatment did not show any inhibitory effect on VEGF induction. These results indicate that ERKs and intracellular stored calcium release play a critical role in VEGF induction by vanadium. PI-3K is partially involved in VEGF induction by vanadium, while p38K and mTOR are not involved. Those results will help us to understand the molecular mechanisms involved in vanadium-induced biological effects.
authors.affiliation: Nelson Institute of Environmental Medicine, School of Medicine, New York University, Old Forge Road, Tuxedo, New York 10987, USA.
authors.forename: Jingxia
authors.initials: J
authors.lastname: Li
authors.forename: Qiangsong
authors.initials: Q
authors.lastname: Tong
authors.forename: Xianglin
authors.initials: X
authors.lastname: Shi
authors.forename: Max
authors.initials: M
authors.lastname: Costa
authors.forename: Chuanshu
authors.initials: C
authors.lastname: Huang
mesh_terms: D000818:Animals; D020013:Calcium Signaling / Q000187:drug effects*; D002460:Cell Line; D002614:Chelating Agents; D002867:Chromones; D004533:Egtazic Acid / Q000031:analogs & derivatives; D004791:Enzyme Inhibitors; D004817:Epidermis; D005419:Flavonoids; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051379:Mice; D009025:Morpholines; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D013997:Time Factors; D014162:Transfection; D014639:Vanadium / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*
chemical_list: D002614:Chelating Agents; D002867:Chromones; D004533:Egtazic Acid; D004791:Enzyme Inhibitors; D005419:Flavonoids; D020930:MAP Kinase Kinase Kinases; D009025:Morpholines; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D014639:Vanadium; D042461:Vascular Endothelial Growth Factor A; C070379:1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one